We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

257 hedge funds and large institutions have $1.51B invested in CRISPR Therapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 97 increasing their positions, 54 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 54

30% more call options, than puts

Call options by funds: $41.5M | Put options by funds: $31.8M

14% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 44

5.14% more ownership

Funds ownership: 53.3% → 58.44% (+5.1%)

2% more funds holding

Funds holding: 253 → 257 (+4)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

22% less capital invested

Capital invested by funds: $1.92B → $1.51B (-$416M)

Holders
257
Holders Change
+4
Holders Change %
+1.58%
% of All Funds
5.66%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
50
Increased
97
Reduced
54
Closed
44
Calls
$41.5M
Puts
$31.8M
Net Calls
+$9.67M
Net Calls Change
+$12.2M

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$68.6M
2
NAMA
Nikko Asset Management Americas
New York
+$37M
3
Morgan Stanley
Morgan Stanley
New York
+$30.8M
4
TCM
TimesSquare Capital Management
New York
+$18.8M
5
Ameriprise
Ameriprise
Minnesota
+$17.9M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$19.1M
2
Millennium Management
Millennium Management
New York
-$19M
3
Two Sigma Investments
Two Sigma Investments
New York
-$11.9M
4
O
OrbiMed
New York
-$11.1M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$9.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
GWMIA
226
Global Wealth Management Investment Advisory
Florida
$6K – – –
RWA
227
Ropes Wealth Advisors
Massachusetts
$6K – – –
SIM
228
Sonora Investment Management
Arizona
$6K +$2.32K +45 +45%
Fidelity International
229
Fidelity International
Bermuda
$5K +$5.73K +111 New
GAM
230
Gemmer Asset Management
California
$5K +$6.45K +125 New
CT
231
Caldwell Trust
Florida
$4.24K +$5.16K +100 New
CFGS
232
Concourse Financial Group Securities
Alabama
$4K – – –
LWM
233
Liberty Wealth Management
California
$4K – – –
PK
234
Pflug Koory
Nebraska
$4K – – –
BFC
235
Bedel Financial Consulting
Indiana
$4K +$5.16K +100 New
WQ
236
Wealth Quarterback
New Jersey
$3.18K – – –
TCM
237
Tradewinds Capital Management
Washington
$3K -$775 -15 -20%
BWP
238
Baldwin Wealth Partners
Massachusetts
$3K – – –
CCM
239
Cribstone Capital Management
Maine
$3K – – –
LF
240
Lee Financial
Texas
$3K – – –
MF
241
Manchester Financial
California
$3K – – –
Simplex Trading
242
Simplex Trading
Illinois
$3K +$4.7K +91 New
CAC
243
Certified Advisory Corp
Florida
$2K – – –
HGWM
244
Harvest Group Wealth Management
Massachusetts
$2K – – –
PP
245
Pacifica Partners
Canada
$2K – – –
TFA
246
Toth Financial Advisory
Virginia
$2K +$2.06K +40 New
GI
247
Gradient Investments
Minnesota
$2K +$2.43K +47 New
MAM
248
Meeder Asset Management
Ohio
$1K – – –
OPS
249
Orion Portfolio Solutions
Nebraska
$1K – – –
SBL
250
Sargent Bickham Lagudis
Colorado
$1K – – –
8 9
10
11 12

CRSP Hedge Fund Activity: Q1 2020 in Review

257 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2020, worth a combined $1.51B — down 22% from $1.92B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new CRSP positions and 44 closed out — a net gain of 6 holders — while 97 added to existing stakes and 54 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $68.6M. The largest seller was Cormorant Asset Management, cutting an estimated $19.1M.

  • 257 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2020, up from 253 in Q4 2019.
  • Funds reported $1.51B of CRISPR Therapeutics stock for Q1 2020, down 22% quarter-over-quarter.
  • 50 funds opened new CRISPR Therapeutics positions in Q1 2020 and 44 closed out, a net change of +6 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2020 was ARK Investment Management, an estimated $68.6M added.
  • The largest CRISPR Therapeutics seller in Q1 2020 was Cormorant Asset Management, an estimated $19.1M sold.

Based on aggregated 13F filings for Q1 2020.